Drug Search Results
More Filters [+]

QBM-076

Alternative Names: qbm-076, qbm076, qbm 076
Latest Update: 2022-03-28
Latest Update Note: Clinical Trial Update

Product Description

Novartis was developing qbm-076, an oral CXCR2 Antagonist for Chronic Obstructive Pulmonary Disease . (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01972776)

Mechanisms of Action: CXCR2 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for QBM-076

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Chronic Obstructive Pulmonary Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2012-005615-92

P2

Terminated

Chronic Obstructive Pulmonary Disease

2015-06-12

CQBM076X2203

P2

Terminated

Chronic Obstructive Pulmonary Disease

2015-05-01

Recent News Events

Date

Type

Title